Wednesday, July 8, 2026

biotech · Parkinson Disease · Amyotrophic Lateral Sclerosis · DNLI

Denali Therapeutics

Denali Therapeutics clinical programs — 23 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

161 Oyster Point Blvd, South San Francisco, California 94080, US HQ
2015 Founded
567 Employees
Public company Type
DNLI · NYSE Ticker
Company details
Status
Public
HQ
161 Oyster Point Blvd, South San Francisco, California 94080, US
Founded
2015
Employees
567
Programs
23
Drugs
10
Patents
42
Intelligence · Clinical Programs

Denali Therapeutics projects

23 ClinicalTrials.gov programs sponsored by Denali Therapeutics.

Denali Therapeutics has 23 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. BIIB122

    Denali Therapeutics

    Parkinson Disease

    phase 3 small molecule active

    2 trials
  2. DNL343

    Denali Therapeutics

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule completed

    2 trials
  3. Elaprase 2 mg/ml concentrate for solution for infusion

    Denali Therapeutics

    Mucopolysaccharidosis Type II [MPS II]

    phase 3 small molecule active

    1 trial
  4. tividenofusp alfa

    Denali Therapeutics

    Mucopolysaccharidosis II

    phase 3 small molecule active

    3 trials
  5. BIIB122 225 mg

    Denali Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial
  6. BIIB122, Placebo to BIIB122

    Denali Therapeutics

    Parkinson’s disease

    phase 2 small molecule active

    1 trial
  7. DNL126

    Denali Therapeutics

    Mucopolysaccharidosis Type IIIA

    phase 2 small molecule active

    1 trial
  8. DNL593

    Denali Therapeutics

    Frontotemporal Dementia

    phase 2 small molecule active

    1 trial
  9. DNLI-E-0002

    Denali Therapeutics

    Hunter Syndrome (Mucopolysaccharidosis Type II [MPS II])

    phase 2 other active

    1 trial
  10. DNLI-H-0001

    Denali Therapeutics

    Frontotemporal Dementia (FTD)

    phase 2 small molecule active

    1 trial
  11. BIIB122 (DNL151)

    Denali Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  12. DNL151

    Denali Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  13. DNL201

    Denali Therapeutics

    Parkinson Disease

    phase 1 small molecule completed

    1 trial
  14. DNL201

    Denali Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  15. DNL343

    Denali Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials
  16. DNL628

    Denali Therapeutics

    Alzheimer Disease, Early Onset

    phase 1 small molecule active

    1 trial
  17. DNL747

    Denali Therapeutics

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial
  18. DNL747

    Denali Therapeutics

    Amyotrophic Lateral Sclerosis

    phase 1 small molecule terminated

    1 trial
  19. DNL919

    Denali Therapeutics

    Healthy Participant

    phase 1 small molecule completed

    1 trial
  20. DNL952

    Denali Therapeutics

    Late-onset Pompe Disease

    phase 1 small molecule active

    1 trial
  21. DNLI-K-0001

    Denali Therapeutics

    Early Alzheimer's Disease

    phase 1 other active

    1 trial
  22. [14C] BIIB122 ([14C] DNL151)

    Denali Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  23. [14C]-DNL343

    Denali Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Denali Therapeutics have?

23 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.